ClinicalTrials.gg
RecruitingNCT03875781NORAD01Updated Jan 15, 2026

Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

A Phase 3 interventional study of Chemotherapy and Radiochemotherapy in Rectal Cancer and Advanced Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.

Planned enrollment
16th of 120
540 · median 109
Started
2019
with 7 others
Phase 3
37 of 160
3 open now
Primary completion
2026-12
later than 15 of 39 live
Registered
106th of 160
by date
Lead sponsor
9 of 160
Assistance Publique - Hôpitaux de Paris

Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 16th largest by planned enrollment of the 120 interventional ones that give a count, is one of 8 that started in 2019, is one of 37 in phase 3, reaches primary completion later than 15 of the 39 other live ones, and was the 106th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Rectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

This study is a non-inferiority phase III randomised trial comparing preoperative chemotherapy alone (modified FOLFIRINOX) to chemotherapy followed by chemoradiotherapy in patients with primary resectable locally advanced rectal cancer. The primary endpoint of the study is 3-year progression free survival.

Expected 3 year PFS rate in the preoperative chemotherapy followed by chemoradiotherapy arm is 75%. This hazard rate, in an exponential survival model, corresponds to a decrease in the 3-year PFS rate on the preoperative chemotherapy arm to 67%. The study will randomize 540 patients (270 in the chemotherapy group and 270 in the chemoradiotherapy group) in 42 french academic centers.

Read the detailed description

This study is a national, multicenter, open-label randomized, 2-arm phase III non-inferiority trial.

Patients with mid or low LARC (cT3N0 or cT1-T3N+ with CRM > 2 mm on pretreatment MRI) will be randomized to two arms of treatment: one experimental arm with systemic FOLFIRINOX chemotherapy for 3 months and one control arm with systemic FOLFIRINOX chemotherapy for 3 months followed by conventional standardized radiochemotherapy (intensified-modulated radiotherapy 50Gy + capecitabine). The choice of FOLFIRINOX for preoperative chemotherapy is based on recent data regarding its safety and efficacy rectal cancer with or without metastatic disease. Since the annual world meeting of ASCO 2020, a new standard of treatment has been adopted using the combination of chemotherapy followed by radiochemotherapy that has been show to improve disease free survival in phase III controlled randomized trial (Conroy et al, J Clin Oncol 38: 2020 (suppl; abstr 4007).

All patients will have reassessment MRI after preoperative treatment and before surgery.

Objectives and study endpoints

- primary endpoint : 3-year progression-free survival (PFS) from the time to randomization. In this trial, a modified definition of PFS will be used for the primary endpoint. The rationale for using this modified definition of PFS is to better assess time to failure of the whole treatment strategy (preoperative treatment and surgery).

Progression will be assessed as follows:

  • progression during preoperative treatment and before surgery: circumferential resection margin ≤ 2mm at MRI reeassessemnt and diagnosis of any new distant lesion whatever the site (liver, lung, peritoneum, adrenal) are considered as progression events.
  • progression after surgery: recurrence/progression after surgery or death, whatever comes first.

    • Secondary endpoints: treatment related toxicity, treatment compliance, R0 resection rate, sphincter saving surgery rate, postoperative morbidity and mortality rates, loco-regional recurrence free survival, overall survival, bowel and sexual functions at diagnosis, quality of life, radiologic and pathologic response after preoperative treatment.

Statistical analysis A sample size of 518 patients, based on an expected accrual duration of 36 months, 60 months follow-up, and an expected 3 year PFS rate in the preoperative chemotherapy followed by chemoradiotherapy arm of 75%, is expected to provide 239 PFS events required to provide 80% power to declare non-inferiority of the preoperative chemotherapy arm when the true hazard ratio between arms is 1.0 (H1). This design has a global type one-error rate of 0.05 if the true hazard ratio between arms is 1.39 (H0). This hazard rate, in an exponential survival model, corresponds to a decrease in the 3-year PFS rate on the preoperative chemotherapy arm to 67%. By considering a rate of 4% for not informative or lost to follow-up patients the total number of patients to be included in this trial was 518*100/96 = 540 patients.

Ancillary studies Pronostic value of circulating cancer cells before and after preoperative treatment and after surgery in patients undergoing surgery for rectal cancer after chemotherapy or radiochemotherapy will be evaluated. After assessment of prognostic value of each rate on survival, recurrence and response to treatment, evaluation of prognostic impact of variation of the rate during differents phases of treatment will be carried out.

03

Conditions studied

  • Rectal Cancer
  • Advanced Cancer

Browse trials for

Keywords

  • Rectal cancer
  • FOLFIRINOX,
  • chemotherapy
  • radiochemotherapy
  • surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven middle or low rectal carcinoma, ≤ 10 cm from the anal verge on MRI (sagittal slide)
  • cT3N0 and/or cT1-T3N+ on pretreatment imaging work up (pelvic contrast enhanced MRI and/or endorectal ultrasound),
  • Pretreatment predictive circumferential margin > 2mm on pretreatment imaging work up (pelvic contrast enhanced MRI)
  • Patients must be 18 years old or older
  • A World Health Organization () performance status of 0 or 1
  • signed
  • Patients of childbearing / should use adequate measures during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

Exclusion criteria

Exclusion Criteria:

  • Rectal tumor > 10 cm from the anal verge on MRI (sagittal slide)
  • cT4 tumor on pretreatment imaging work up (pelvic contrast enhanced MRI and/or endorectal ultrasound) or involvement of external sphincter
  • Circumferential margin ≤ 2 mm on pretreatment imaging work up (pelvic contrast enhanced MRI)
  • disease
  • Prior pelvic irradiation or any to pelvic irradiation
  • Contraindication to oxaliplatin or irinotecan or 5FU based chemotherapy
  • Concomitant treatment with warfarin is contraindicated and warafarin must be replaced whenever possible to allow for inclusion.
  • Recent or concomitant treatment with brivudine is contraindicated
  • contraindications to 5-FU: complete and permanent insufficiency in dihydropyrimidine dehydrogenase, bone marrow insufficiency, chronic and severe infection
  • contraindication to irinotecan : inflammatory bowel disease, serum level > 3 times the rate, severe bone marrow insufficiency, performence status > 2,
  • Concomitant treatment with millepertuis.
  • contraindication to oxaliplatin :

    *bone marrow insufficiency before treatment initiation ( \<2x109/L and/or count \<100x109/L), peripheral neuropathy with permanent invalidity before treatment initiation

  • severe renal insufficiency (Creatinin clearance \<30 ml/min)
  • contraindications to folinic acid : Biermer anemia and other anemia related to B12 vitamin insufficiency
  • contraindications to capecitabin : severe renal insufficiency (Creatinin clearance \<30 ml/min), complete and permanent insufficiency in dihydropyrimidine dehydrogenase
  • should not be used during and 6 months after preoperative treatment.
  • Previous colorectal cancer
  • Other concomitant or previous , except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years
  • Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • protected adults
  • Pregnancy or breastfeeding
  • Patient with no national health or universal plan affiliation coverage.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    A: Modified Folfirinox

    Experimental : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.

    Drug: Chemotherapy

  • Active comparator
    B: Modified Folfirinox followed by Radiochemotherapy

    Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor

    Drug: Radiochemotherapy

Interventions

  • DrugChemotherapy

    Arm A : Experimental * Intervention Type : Drug * Intervention Name : Modified FOLFIRINOX (experimental arm) * Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.

  • DrugRadiochemotherapy

    Arm B: Active comparator * Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm) * Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor.

06

What researchers measure

Primary outcomes

  1. Survival

    3-year progression-free survival

    Time frame: 3 years

Secondary outcomes

  1. Acute treatment toxicity

    Acute and late treatment related toxicity: the rates of treatment related toxicity grade II or more

    Time frame: Up to 1 month after the end of preoperative treatment

  2. Late toxicity related to treatment

    Late treatment related toxicity: the rates of treatment related toxicity grade II or more

    Time frame: 3 years after surgery

  3. Compliance to treatment

    The rate of patients that receive full dose treatment

    Time frame: Up to 1 month after the end of preoperative treatment

  4. Radiological response

    Radiologic response on post-treatment MRI based on tumor size reduction and tumor regression grade (ymrTRG)

    Time frame: 28±5 days after the end of preoperative treatment

  5. The rate of R0 resection

    Rate of complete resection with safe \> 1mm circumferential and longitudinal margin

    Time frame: 4 weeks after surgery

  6. Quality of mesorectal excision: 3-grades Quirke scoring system

    3-grades Quirke scoring system of the quality of mesorectal excision

    Time frame: 4 weeks after surgery

  7. Number of lymph nodes harvested

    A count of number of lymph nodes harvested

    Time frame: 4 weeks after surgery

  8. Size of circumferential margin

    Mesurement of circumferential margin

    Time frame: 4 weeks after surgery

  9. Size of longitudinal margin

    Mesurement of longitudinal margin

    Time frame: 4 weeks after surgery

  10. Sphincter saving surgery rate

    The rate of surgery with intestinal continuity and anal sphincter preservation

    Time frame: 4 weeks after surgery

  11. Postoperative morbidity

    Postoperative morbidity: 30 day or in-hospital postoperative morbidity rates

    Time frame: 30 days after resection

  12. Postoperative mortality

    Postoperative mortality: 30 day or in-hospital postoperative mortality rates

    Time frame: 30 days after resection

  13. Pathologic response after chemotherapy

    Pathologic response on Rodel Tumor Regression Grade

    Time frame: 4 weeks after surgery

  14. Pathologic response after chemoradiotherapy

    Pathologic response after chemoradiotherapy: rate of major pathologic response base on Rodel Tumor Regression Grade

    Time frame: 4 weeks after surgery

  15. Loco-regional recurrence free survival

    Loco-regional recurrence free survival: 3-year locoregional recurrence free survival rates

    Time frame: At 3 years

  16. Uncontrolled local recurrence

    Uncontrolled local recurrence: 3-year uncontrolled local recurrence free survival rates

    Time frame: At 3 years

  17. Overall survival

    Overall survival: 3 year overall survival rates

    Time frame: At 3 years

  18. Overall survival

    Overall survival: 5 year overall survival rates

    Time frame: At 5 years

  19. EORTC QLQ-CR29

    Assessed by the validated scales of quality of life for Colorectal Cancer Patients (QLQ-CR29) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 25 to 104 (104 is the worst quality of life)

    Time frame: Diagnosis time

  20. EORTC QLQ-CR29

    Assessed by the validated scales of quality of life for Colorectal Cancer Patients (QLQ-CR29) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 25 to 104 (104 is the worst quality of life)

    Time frame: 28±5 days after the end of preoperative treatment

  21. EORTC QLQ-CR29

    Assessed by the validated scales of quality of life for Colorectal Cancer Patients (QLQ-CR29) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 25 to 104 (104 is the worst quality of life)

    Time frame: At 6 months after surgery

  22. EORTC QLQ-CR29

    Assessed by the validated scales of quality of life for Colorectal Cancer Patients (QLQ-CR29) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 25 to 104 (104 is the worst quality of life)

    Time frame: 1 year after surgery

  23. LARS Scores

    Bowel function assessed by the Low Anterior Resection Syndrome (LARS) score. The score ranges from 0 to 42 (42 is the most severe LARS)

    Time frame: Diagnosis time

  24. LARS Scores

    Bowel function assessed by the Low Anterior Resection Syndrome (LARS) score. The score ranges from 0 to 42 (42 is the most severe LARS)

    Time frame: 28±5 days after the end of preoperative treatment

  25. LARS Scores

    Bowel function assessed by the Low Anterior Resection Syndrome (LARS) score. The score ranges from 0 to 42 (42 is the most severe LARS)

    Time frame: 6 months after surgery

  26. LARS Scores

    Bowel function assessed by the Low Anterior Resection Syndrome (LARS) score. The score ranges from 0 to 42 (42 is the most severe LARS)

    Time frame: 1 year after surgery

  27. Quality of life - physical functioning: QLQ-C30

    Health related physical functioning assessed by the validated scale for Cancer Patients (QLQ-C30) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 0 to 100 (100 is the worst physical functioning)

    Time frame: At diagnosis

  28. Quality of life - physical functioning: QLQ-C30

    Health related physical functioning assessed by the validated scale for Cancer Patients (QLQ-C30) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 0 to 100 (100 is the worst physical functioning)

    Time frame: 28±5 days after the end of preoperative treatment

  29. Quality of life - physical functioning: QLQ-C30

    Health related physical functioning assessed by the validated scale for Cancer Patients (QLQ-C30) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 0 to 100 (100 is the worst physical functioning)

    Time frame: 6 months after surgery

  30. Quality of life - physical functioning: QLQ-C30

    Health related physical functioning assessed by the validated scale for Cancer Patients (QLQ-C30) of the European Organisation for Research and Treatment of Cancer (EORTC). The scales ranges from 0 to 100 (100 is the worst physical functioning)

    Time frame: 1 year after surgery

07

Study locations

1 of 1 sites recruiting
  • BENOIST
    Le Kremlin-Bicêtre, Île-de-France Region 94275, France
    Recruiting
08

References and documents

Publications

  • Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. doi: 10.1056/NEJMoa060829. PubMed 16971718 ↗
  • Wiltink LM, Chen TY, Nout RA, Kranenbarg EM, Fiocco M, Laurberg S, van de Velde CJ, Marijnen CA. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014 Sep;50(14):2390-8. doi: 10.1016/j.ejca.2014.06.020. Epub 2014 Jul 21. PubMed 25060825 ↗
  • Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13. PubMed 24419115 ↗
  • Bensignor T, Brouquet A, Dariane C, Thirot-Bidault A, Lazure T, Julie C, Nordlinger B, Penna C, Benoist S. Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation. Colorectal Dis. 2015 Jun;17(6):491-8. doi: 10.1111/codi.12879. PubMed 25524450 ↗
  • Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, Chen D, Cao J, Wei H, Peng X, Huang Z, Cai G, Zhao R, Huang Z, Xu L, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Zhou Z, Cai Y, Kang L, Huang M, Peng J, Ren D, Wang J. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol. 2016 Sep 20;34(27):3300-7. doi: 10.1200/JCO.2016.66.6198. Epub 2016 Aug 1. PubMed 27480145 ↗
  • Brouquet A, Bachet JB, Huguet F, Karoui M, Artru P, Sabbagh C, Lefevre JH, Vernerey D, Mariette C, Vicaut E, Benoist S; on behalf the FRENCH , GRECCAR, PRODIGE study groups. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial). BMC Cancer. 2020 May 29;20(1):485. doi: 10.1186/s12885-020-06968-1. PubMed 32471382 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 90 months is above that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2019
First posted
Mar 15, 2019
StartActual
Jun 5, 2019
Primary completionEst.
Dec 5, 2026
CompletionEst.
Dec 5, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03875781
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Jun 5, 2019
Primary completion
Dec 5, 2026 (estimated)
Completion
Dec 5, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

Stéphane BENOIST, MD,PHD
Contact
stephane.benoist@aphp.fr
+ 33 1 45 21 34 72
Antoine BROUQUET, MD,PHD
Contact
antoine.brouquet@aphp.fr
+ 33 1 45 21 34 70
Stéphane BENOIST, MD,PHD
study chair · Service de chirurgie digestive et oncologique Hôpital Bicêtre - 94275 LE KREMLIN BICETRE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion